Takeda Pharmaceutical (NYSE:TAK) Now Covered by Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Takeda Pharmaceutical (NYSE:TAK) in a report published on Tuesday. The firm issued an overweight rating on the stock.

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Takeda Pharmaceutical has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $16.01 on Tuesday. The stock’s 50-day moving average is $14.77 and its two-hundred day moving average is $14.69. The firm has a market cap of $50.93 billion, a price-to-earnings ratio of 200.06 and a beta of 0.03. Takeda Pharmaceutical has a 1 year low of $12.80 and a 1 year high of $16.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, meeting the consensus estimate of $0.44. The business had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Analysts predict that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. increased its position in shares of Takeda Pharmaceutical by 29.1% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 15,112 shares of the company’s stock valued at $234,000 after buying an additional 3,410 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 21.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock worth $87,000 after buying an additional 1,003 shares in the last quarter. Parallel Advisors LLC grew its stake in Takeda Pharmaceutical by 22.6% in the 2nd quarter. Parallel Advisors LLC now owns 24,338 shares of the company’s stock valued at $376,000 after acquiring an additional 4,485 shares during the last quarter. Capital Fund Management S.A. increased its holdings in Takeda Pharmaceutical by 216.1% during the 2nd quarter. Capital Fund Management S.A. now owns 126,279 shares of the company’s stock valued at $1,952,000 after acquiring an additional 86,333 shares in the last quarter. Finally, QRG Capital Management Inc. increased its holdings in Takeda Pharmaceutical by 11.8% during the 2nd quarter. QRG Capital Management Inc. now owns 432,654 shares of the company’s stock valued at $6,689,000 after acquiring an additional 45,726 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.